Skip to main content
. 2019 Sep 6;16:25. doi: 10.1186/s12981-019-0240-4

Table 2.

Participant characteristics in HIV cure trials

Study agents RV411 RV397 RV409 RV405
N/A VRC01 Placebo VHM Placebo Ad26/MVA Placebo
Number of participants 8 13 5 10 5 17 9
Median age 29 32 25 28 26 24 25
Male (%) 87.5 100 100 89 75 100 100
Median HIV RNA pre-ART, log10 c/mL 4.3 3.1 2.7 6.1 5.6 5.9 6.4
Median CD4, cells/mm3 pre-ART 413 769 552 397 532 633 586
Median CD4/CD8 ratio pre-ART 0.8 1.1 0.9 0.4 0.8 0.6 0.6
Median duration of ART (years) 2.8 3.1 2.7 4.3 3.0 2.2 2.2
Fiebig stage (number) I: 8

I/II: 8

III: 5

I/II: 3

III: 2

III: 8

IV: 2

 III: 5

I: 0

II: 6

III: 6

IV: 5

I: 1

II: 4

III: 4

IV: 0

VHM vorinostat, hydroxychloroquine, maraviroc, Ad26 adenovirus type 26 vector prime, MVA modified vaccinia Ankara, ART antiretroviral therapy